Search Results
Updates on C9orf72 and TDP-43 Research from Dr Jeffrey Rothstein
Katie Irwin TDP-43 Biomarker Talk for Genetic ALS & FTD: End the Legacy
Estimates of C9orf72 Statistics drawn from prior publications including estimated life expectancy
ALS Starts at the Nuclear Pore: Insights and Therapy for ALS and Dementia by Dr. Jeff Rothstein
"Stathmin-2: An Emerging Therapeutic Target in TDP-43 Proteinopathies"
The C9orf72 Repeat Expansion in Broad Population Screens
Aaron Gitler Talk with Genetic ALS / FTD Community
TPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&A
R. Baloh - Cellular and animal models to understand C9ORF72 repeat expansion in ALS and FTLD
Genetic Mutations in Parents May Increase Risk of ALS in Children
M. Neumann - TDP-43 , FUS and beyond...
An Update on Exercise in People at Genetic Risk of ALS & FTD: Daniel Brickman, PHD
